MH & Associates Securities Management Corp ADV Invests $4.33 Million in Teva Pharmaceutical Industries Ltd. $TEVA

MH & Associates Securities Management Corp ADV acquired a new position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 138,731 shares of the company’s stock, valued at approximately $4,330,000. Teva Pharmaceutical Industries accounts for approximately 3.5% of MH & Associates Securities Management Corp ADV’s investment portfolio, making the stock its 4th largest position.

A number of other institutional investors have also made changes to their positions in the business. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Teva Pharmaceutical Industries by 3.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 11,911 shares of the company’s stock valued at $382,000 after purchasing an additional 379 shares during the last quarter. Howard Bailey Securities LLC boosted its stake in shares of Teva Pharmaceutical Industries by 3.5% in the 3rd quarter. Howard Bailey Securities LLC now owns 14,451 shares of the company’s stock valued at $292,000 after purchasing an additional 494 shares during the last quarter. ASR Vermogensbeheer N.V. boosted its stake in shares of Teva Pharmaceutical Industries by 1.6% in the 3rd quarter. ASR Vermogensbeheer N.V. now owns 31,915 shares of the company’s stock valued at $645,000 after purchasing an additional 515 shares during the last quarter. CIBC Private Wealth Group LLC boosted its stake in shares of Teva Pharmaceutical Industries by 15.5% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company’s stock valued at $81,000 after purchasing an additional 540 shares during the last quarter. Finally, Retirement Planning Co of New England Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 1.8% in the 3rd quarter. Retirement Planning Co of New England Inc. now owns 33,230 shares of the company’s stock valued at $671,000 after purchasing an additional 588 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Stock Up 4.0%

Teva Pharmaceutical Industries stock opened at $30.50 on Thursday. The company’s 50 day simple moving average is $31.99 and its 200 day simple moving average is $28.02. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $37.35. The firm has a market capitalization of $35.07 billion, a price-to-earnings ratio of 25.42, a PEG ratio of 10.13 and a beta of 0.76. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.31. The business had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. Teva Pharmaceutical Industries’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 62,102 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $30.14, for a total transaction of $1,871,754.28. Following the transaction, the insider directly owned 224,940 shares in the company, valued at approximately $6,779,691.60. The trade was a 21.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Richard Daniell sold 17,295 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $547,732.65. Following the transaction, the executive vice president owned 85,755 shares in the company, valued at approximately $2,715,860.85. This represents a 16.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 920,901 shares of company stock valued at $30,056,789. Company insiders own 0.49% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on TEVA shares. Barclays raised their target price on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research note on Friday, January 30th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. Truist Financial raised their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, January 21st. Finally, Piper Sandler restated an “overweight” rating and issued a $41.00 price target (up from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.